

Index

- 5 α -reductase deficiency, 173, 175
acrosomal response to ionophore challenge (ARIC) score, 15
acrosome, 4–5
 acrosome reaction assays, 14–15
acupuncture, 190
adenohypophysis, 1
adolescents. *See also* pediatric issues
 fertility preservation issues, 271
 varicocele, 262–3
agenesis, seminal vesicles, 48–50
aging, 2
AIDS, 197–8
alcohol abuse, 9, 189
alpha agonists, anejaculation treatment, 115
alpha blockers, retrograde ejaculation and, 131
amantadine, 115
amoxicillin, 289
anabolic steroids, 9
anastrozole, 162–3
 empiric therapy, 189
Andrews Procedure, 153
androgen resistance, 173, 175
androgens. *See also* testosterone
 bone mass relationships, 182
 replacement therapy, Klinefelter syndrome, 182
anejaculation, 105, 116
 epidemiology, 106
 evaluation, 112–14
 idiopathic, 131–2
 neurogenic, 131–2
 treatment options, 114–16
 medical treatment, 115
animal models, 303, *See also* rat
 use in training and research
anorchia, 173
anorgasmia, 105
antiandrogen exposure, 257
antibiotics, 286–9
anti-epileptics, 289
anti-Müllerian hormone (AMH), 222
antioxidant therapy, 187–9
 carnitine, 188
 carotenoids, 188
 folate, 188
 lycopene, 188
 N-acetylcysteine (NAC), 188
 selenium, 189
 vitamin C, 187–8
 vitamin E, 188
anti-retroviral drugs, 289
antisperm antibodies, 234,
 See also autoimmunity to spermatozoa 27–8
 cystic fibrosis and, 29–30
 effects on fertility, 28–9
 routine testing for, 33, 234
antral follicle count, 222
anxiety, sexual dysfunction and, 194
apoplexy of the pituitary, 172
aromatase inhibitors, 162–3, 183, 189
arousal disorders, 116
assisted reproductive technology (ART), 219,
 See also specific techniques
 indications, 219
 risks, 228–9
 statistics, 329
autoimmune testicular failure, 173
autoimmunity to spermatozoa, 27–8, *See also* antisperm antibodies
 etiology, 137–8
 treatments, 30–2
 corticosteroids, 31–2
 in vitro fertilization (IVF), 32–3
 intrauterine insemination (IUI), 32–3
autonomic dysreflexia (AD), 120–1
 home management, 125
azoospermia, 13
 differential diagnosis, 73–4
 nonobstructive, 19, 62, 161,
 See also testicular sperm extraction (TESE)
 diagnostic testicular biopsy, 161–2
 genetic testing, 20–2, 162
 preoperative preparation, 162–3
 treatment considerations, 163
obstructive, 19, 61–2,
 See also epididymal sperm aspiration
 evaluation, 100
 sperm retrieval, 101–3
 testicular biopsy, 61
azoospermic factor (AZF) region, 5, 21
 AZFa, 20
 AZFb, 20
 AZFc, 20, 22
 microdeletions, 22
 genetic testing for, 166
 transmission to male offspring, 22
balloon dilatation of the ejaculatory duct, 57
birth defects, IVF risks, 229
bladder extrophy, 265
blood–testis barrier, 4
body mass index (BMI), 190
bone mineral density, Klinefelter syndrome, 182
Bottle Operation, 153–4
bulbocavernosus reflex (BCR), 120
bulbospongiosus and ischiocavernosus muscle (BCM), 103, 106–10
bulbous urethra (BU) distention, 113
cadmium impact on fertility, 253
calcifications
 ejaculatory ducts, 57
 seminal vesicles, 48
cancer, 197, 269,
 See also chemotherapy;
 radiotherapy; *specific types of cancer*
 direct effects on fertility, 269
 fertility preservation, 269, 271–2
 children, 271–2
 experimental methods, 272
 gonadal protection with hormonal suppression, 271
 gonadal shielding with radiotherapy, 271
 nursing issues, 326–7
 sperm banking, 271, 281–4
 fertility treatment after cancer therapy, 272–3
 pediatric, 264
 treatment effects on fertility, 269–70, 285,
 See also chemotherapy;
 radiotherapy
 anatomical obstruction, 269
 hormonal and gonadotoxic therapies, 269–70
 risks to offspring conceived following therapy, 270–1
 safety to conceive, 286, 294–5
capacitation, 14
carboplatin, 286
carcinoma
 embryonal cell, 41
 testicular, 42
carnitine, 188
carotenoids, 188
cavernosal arteries, 47
central pattern generator (CPG), 107–9
cerebral palsy, 247
cervical mucus
 complement system, 28–9
 penetration by sperm, 29
 antisperm antibody effects, 28
chemotherapy, 9, 197,
 See also cancer
 combination therapies, 285–6
 effects on fertility, 297
 spermatogenesis, 284–6
 fertility treatment after, 272–3
 testicular sperm extraction, 166
 gonadotoxic effects, 269–70
 pediatric, 264
 risks to offspring conceived following therapy, 270–1
 safety to conceive after, 286, 294–5

Index

- children. *See* pediatric issues
Chlamydia trachomatis, 30
chloroquine, 289
choriocarcinoma, 41
chromatin structure, 242–3
cigarette smoking, 9
cimetidine, 9
cisplatin, 286
classification problem, 339–40
clomiphene citrate, 175, 189, 200
 ovarian stimulation, 223, 233–4
 with gonadotropins, 224–5
cocaine, 189
cognitive impairment, Kliefelter syndrome, 181–2
combined male sexual dysfunction and infertility, 193, *See also* infertility; sexual dysfunction
epidemiology, 193–4
etiology, 194–8
 cancer, 197
 diabetes, 196–7
 HIV and AIDS, 197–8
 hormonal disorders, 194–6
 metabolic syndrome and obesity, 196
 psychogenic sexual dysfunction, 194
 sexual dysfunction pharmacotherapy, 198–200
COMET assay, 15, 240
complementary therapy, 187, 189–90
 acupuncture, 190
 environmental exposure prevention, 189–90
 lifestyle treatments, 189
 obesity prevention, 190
computational technology, 339–40
computed tomography (CT)
 penis, 48
 testis, 42
congenital adrenal hyperplasia (CAH), 43, 172
congenital bilateral absence of the vas deferens (CBAVD), 19, 23
 azoospermia and, 61–2
 differential diagnosis, 73
 genetic testing, 20–1
 findings, 22–3
 physical examination, 10
contraception, 341
controlled ovarian stimulation (COH). *See* in vitro fertilization (IVF); intrauterine insemination (IUI)
corticosteroids, 31–2
 autoimmunity to spermatozoa treatment, 31
cost identification analysis, 329
cost–benefit analysis, 329
cost-effectiveness analysis, 329
 IVF, 329–30
 varicocele vs. sperm retrieval, 333–4
 vasectomy reversal vs. sperm retrieval, 333
costs, 328
 analysis and evaluation methods, 329
co-trimoxazole, 289
counter current heat exchange, 2
craniopharyngioma, 171
cryopreservation. *See* sperm cryopreservation; spermatogonial stem cells (SSCs)
cryoprotectants, 292
cryptorchidism, 157, 254, 263–4
 management, 264
cryptozoospermia, 246
cyclophosphamide, 285
cystic fibrosis, 9–10, 20
 antisperm antibodies and, 29–30
 genetic testing, 20–1
 findings, 22–3
cystic fibrosis transmembrane conductance regulator (CFTR), 20–1
 mutation analysis, 22–3
cysts, 75
 ejaculatory duct, 70
 epididymal efferent ducts, 42–5
 Müllerian duct, 57–8, 74
 prostate, 57, 74, 114
 ejaculatory function and, 106
 seminal vesicles, 50, 74
 testicular, 41
dartos pouch creation, 158–9
DAZ (deleted in azoospermia) gene, 5
delayed ejaculation. *See* retarded ejaculation
depression, 208
diabetes mellitus, 9, 109, 111, 196–7
 ejaculatory dysfunction, 131
dibromochloropropane (DBCP), 253
dihydrotestosterone (DHT), 169
 5 α -reductase deficiency and, 173
diminished ovarian reserve, 220–1
direct costs, 328
discrimination, 339
DNA integrity, 15–16, 239–42
 FISH analysis, 15–16
 following cancer therapy, 295
dopamine, 112, 172
dyspareunia, 213–14
effectiveness, 328–9
 IVF, 329
 surgical techniques, 330–3
ejaculation, 105, 107, 130,
 See also anejaculation; ejaculatory dysfunction; sexual response
ejaculatory force scale, 115
medications affecting, 114–15
neurochemical regulation, 111–12
 dopamine, 112
 oxytocin (OT), 112
 serotonin, 112
neuromuscular regulation, 107–9
premature. *See* premature ejaculation
retarded, 105, 211–12
retrograde. *See* retrograde ejaculation
spinal ejaculatory center, 109–11
testosterone role, 112, 195
ejaculatory duct obstruction, 13, 44, 53, 55–6, 73, 94, 98
 classification, 95
 definition, 95
 diagnosis, 96
 history and physical examination, 73
 imaging, 74–5
 vasography, 68, 70–1, 74
 laboratory studies, 73–4
 level of, 56–7
 partial, 73, 75–6
 treatment, 57, 95–6
 complications, 97–8
 outcomes, 97
ejaculatory ducts, 94,
 See also ejaculatory duct obstruction
 anatomy, 94
 calcifications, 57
 cysts, 70
 imaging, 55–7, 71
 manometry device, 97
 opening pressures, 97
 physiology, 94–5
 stricture, 52
ejaculatory dysfunction, 105, 116, *See also* specific disorders
 classification, 131
 decision-making, 134
 etiologies, 130–1
 evaluation, 131–2
 hypoactive, 105
 management, 132
 nursing considerations, 326
ejaculodysnia, 68
electroejaculation, 115–16, 125, 132–4
 nursing considerations, 326
 semen quality, 124
 sperm cryopreservation, 292
embryo transfer, 227–8
 guidelines, 228
embryonal cell carcinoma, 41
emission, 105
 nocturnal emissions, 112–13
empiric therapy
 antioxidant treatment, 187–9
 definition, 187
endocrine-related infertility.
 See also hypogonadism; testicular failure
 5 α -reductase deficiency, 173
 androgen resistance, 173
 assessment by physical examination, 170
 differential diagnosis, 171
 laboratory assessment, 170–1
 treatment, 173–5
endometrial co-culture, 226
endometriosis, 221
end-stage renal disease, 9
environmental exposure prevention, 189–90
environmental impacts on fertility, 253
 pitfalls with epidemiological studies, 253–4, 258
 testicular dysgenesis syndrome (TDS), 254–6
 toxicological perspectives, 256–7
 studies of abnormal fetal development, 257
 studies of laboratory animals, 256–7
Eosin Y stain, 14
epidermoid inclusion cysts, 41
epididymal cyst, 11
epididymal obstruction. *See also* vasoepididymostomy (VE)
 diagnosis, 86
 indications, 85–6
 management options, 86
epididymal sperm aspiration, 101
 complications, 102
 microsurgical (MESA), 101–2, 291
 percutaneous (PESA), 101–2
epididymis, 5,
 See also epididymal obstruction
 efferent duct cysts, 42–5
 examination, 11
 functions, 5
 head atrophy, 44
 imaging, 42–6
epididymitis, 8, 44–5
erectile dysfunction (ED), 210
 diabetes and, 196
 etiology, 210
 infertility and, 210

- Iranian study, 193
metabolic syndrome and, 196
nursing considerations, 326
treatment, 206, 211
 phosphodiesterase 5 inhibitors (PDE5i), 198–9, 206, 211
- erythromycin, 289
- estradiol
 male sexual function and, 195
 measurement, 170–1
- estrogen, regulatory role, 1
- evolutionary theory, 338–9
- examination. *See* physical examination
- executive skill impairment, Klinefelter syndrome, 181
- fallopian tubes, 219,
 See also tubal factor infertility
- family history 9
- Ferti Care, 120
- fertility preservation in cancer patients. *see* cancer
- fibrous sheath dysplasia, 23
- fine needle aspiration (FNA), 163
- Fleishlight, 114
- fluorescence in situ hybridization (FISH), 227
 sperm analysis, 16
- folate, 188
- follicle-stimulating hormone (FSH), 1, 169
 as predictor of sperm retrieval success, 165–6
 hypogonadotropic hypogonadism, 171
 isolated deficiency, 171
 measurement, 170
 ovarian reserve testing, 222
 ovarian stimulation, 223
 recombinant FSH treatment, 174
 regulation, 1
- freeze-drying of sperm, 293–4,
 See also cryopreservation of sperm
- genetic testing
 candidates for, 19–20
 CBAVD patients, 20–3
 findings, 21–3
 nonobstructive azoospermic patients, 20–2, 162
 Y chromosome microdeletions, 166
 severely oligospermic patients, 20–2
- genital examination, 10–11
- genitourinary infections, 222
- genomics, 337–8
- globozoospermia, 14, 23
- gonadal suppression, 271
- gonadotropin-releasing hormone (GnRH), 1, 169
 GnRH therapy, 174
 Kallman syndrome and, 171
 output rhythms, 1
 gonadotropins, ovarian stimulation, 223–4, 234
 with clomiphene citrate, 224–5
 gynecomastia, 170
- heat exposure, 9
- hemangioendothelioma, 51
- hematocele, 45
- hematoma
 biopsy complications, 65
 intratesticular, 40
 spermatic cord, 48
- hematospermia, 48
- herbal supplementations, 289–90
- hernia repair, 264,
 See also inguinal hernia repair
- hexachlorobiphenyl (CB-153), 254
- hip flexor response (HR), 120
- history taking, 8–9
 childhood illnesses, 8–9
 family history, 9
 genitourinary infections, 222
 medications, recreational drugs, and gonadotoxins, 9
 sexual and reproductive history, 8
 surgical history, 9
 systemic medical illnesses, 9
- HIV infection, 197–8
- Hodgkin's disease, 284
- hormonal therapy advances, 341
- human chorionic gonadotropin (hCG), 174
 ovulation induction, 224
 side effects, 224
- human menopausal gonadotropin (hMG), 174
 ovarian stimulation, 223
 with clomiphene citrate, 225
- hydrocele, 45–6, 150
 diagnosis, 151
 etiology, 150–1
 exudative, 46
 treatment, 152
 complications, 154
 excision techniques, 153–4
 fluid aspiration and sclerotherapy, 152
 indications, 152
 plication techniques, 154–5
 surgical management, 152–4
- hydroxyurea, 289
- hyperprolactinemia, 195–6
- hyperthyroidism, 196
- hypoactive ejaculatory dysfunction, 105
- hypoactive sexual desire disorder (HSDD), 209–10
 infertility and, 209
 management, 209–10
 partner/relationship issues, 209
- hypogonadism, 73
 differential diagnosis, 171
 hypogonadotropic, 10, 171
 isolated (IHH), 171
 pituitary diseases, 171–2
 treatment, 173–4
 physical examination
 implications, 170
 sexual dysfunction and, 194–5
- hypospadias, 254–5
- hypothalamic–pituitary–testis axis. *See* male reproductive hormonal axis
- hypothalamus, 1, 169
- hypothyroidism, 196
- hysterosalpingography (HSG), 220
- idiopathic primary epididymal obstruction.
 See also epididymal obstruction, 86
- immotile cilia syndrome, 9, 23
- Immunobead binding test (IBT), 27, 234
- immunoglobulin. *See* antisperm antibodies
- imperforate anus, 264
- in vitro fertilization (IVF)
 autoimmunity to spermatozoa treatment, 32–3
 autologous endometrial co-culture, 226
 background, 219
 cost-effectiveness, 329–30
 diagnostic work-up, 222
 infections, 222
 ovarian reserve testing, 222
 uterus, 222
 effectiveness, 329
 embryo transfer, 227–8
 guidelines, 228
 health maintenance, 222–3
 indications, 219
 diminished ovarian reserve, 220–1
 endometriosis, 221
 male factor infertility, 220
 tubal factor infertility, 219–20
 unexplained infertility, 221
 male partner evaluation, 222
 nursing considerations, 325–6
 oocyte evaluation, 225
 oocyte insemination, 225–6
 oocyte retrieval, 225
 ovarian stimulation, 223–5
 clomiphene citrate, 223
 clomiphene citrate and gonadotropins, 224–5
 gonadotropins, 223–4
 natural cycle, 223
 patient selection, 221–2
 pregnancy outcomes, 229
 risks, 228–9
- indirect costs, 328
- infections, 222
 IVF complications, 228–9
- infertility, 204,
 See also combined male sexual dysfunction and infertility prevalence, 219
 sexual impact of, 204–5
 unexplained, 221
- infliximab, 289
- inguinal hernia repair, 9, 70
- vasovasostomy and, 82
- inhibin, 1, 3, 169
 measurement, 171
- intracytoplasmic sperm injection (ICSI), 222, 226, 237–8
 chromosome content and, 243
 cryopreserved sperm.
 See sperm cryopreservation
 DNA integrity and chromosome packaging, 239–43
 morphological sperm selection, 243–4
 oocyte activation, 238–9
 results, 244–7
 extended sperm search, 246
 pregnancy characteristics, 246–7
 with ejaculated spermatozoa, 244
 with non-obstructive azoospermia, 246
 with obstructed azoospermia, 244
 with virtual azoospermia, 246
- safety, 247–8
 sperm genomic competence, 237
- intrauterine insemination (IUI), 220, 233
 autoimmunity to spermatozoa treatment, 32–3, 234
 complications, 235
 indications, 233
 male factor infertility, 234
 number per cycle, 235
 ovarian stimulation, 233–4
 technique, 234–5
 type of catheter, 235
 timing, 235

Index

- intravaginal insemination (IVI)
home insemination following
penile vibratory
stimulation, 125–6
- isolated hypogonadotropic
hypogonadism (IHH),
171
- Kallmann syndrome, 9, 171
- Kartagener's syndrome, 9–10
- karyotypic anomalies, 21–2
- KLHL10 gene, 337
- Klinefelter syndrome, 9, 21,
172–3, 179
assisted reproductive
techniques, 181
cognitive function, 181–2
incidence, 179
laboratory evaluation, 180
low bone mineral density, 182
management, 182–3
fertility, 183
pathophysiology, 179–80
testicular function
development, 180–1
adolescence and
adulthood, 180–1
childhood, 180
fetal period, 180
testicular sperm extraction
(TESE), 166
- knot tying, 309–11
- language skill impairment,
Klinefelter syndrome,
181–2
- lead impact on fertility, 253
- Leydig cell tumors, 41–2
- Leydig cells, 2–3,
See also testosterone
aging effects, 2
antibodies to, 173
dysfunction in Klinefelter
syndrome, 180
varicocele effects, 138
- lifestyle complementary
treatments, 189
- lipoma, 48
- liposarcoma, 48
- longitudinal intussusception
vasoepididymostomy
(LIVE), 85, 92
- lubricants, 190
- lumbar spinothalamic tract (LSt)
neurons, 103–4, 108–10
- luteinizing hormone (LH), 1, 169
hypogonadotropic
hypogonadism, 171
isolated deficiency, 171
measurement, 170
regulation, 1
- lycopena, 188
- magnetic resonance imaging
(MRI), 58
ejaculatory ducts, 56
- penis, 47–8
spermatic cords, 46
testis, 42
varicoceles, 46
- male contraception, 341
- male reproductive hormonal
axis, 1–2
development, 1–2
- male sexual dysfunction (MSD).
See combined male
sexual dysfunction
and infertility; sexual
dysfunction
- male sexuality, 204–5
- marijuana, 189
- Massachusetts Male Aging Study
(MMAS), 193
- masturbation retraining, 212
- medial preoptic area (MPOA),
111
- meiotic spindle, 239
- metabolic syndrome, 196
- micro-array technology, 337
- microdissection TESE.
See testicular sperm
extraction (TESE)
- microlithiasis, testicular, 38–41
- microsurgical epididymal sperm
aspiration (MESA), 291,
See also surgical sperm
retrieval (SSR) 101–2
effectiveness, 325–6, 330–2
nursing considerations, 326
- microsurgical instruments, 305
cleaning, 306
learning to use, 307–9
maintenance, 305–6
- microsurgical laboratory
establishment, 304–6
- microsurgical table, 304
- microsurgical training, 303–4
basic preparation, 306–9
microsurgical instrument
use, 307–9
operating microscope use,
307
- laboratory rat use, 318–21
postoperative evaluation,
320–1
vasal obstruction model, 318
vasoepididymostomy,
318–20
vasovasostomy, 318
silicone tubing use, 312–15
suturing technique, 309–12
training models, 303–4
animal models, 303
vasectomy segment use, 316–17
- midronine, 115
- mixed antiglobulin reaction
(MAR), 27, 234
- molecular imaging, 340
- motile sperm organelle
morphology
examination (MSOME),
243
- müllerian duct cysts, 57–8, 74
- müllerian inhibiting substance, 1
- multiple gestations, 228
- multiple sclerosis, 9
- mumps orchitis, 8
- myelomeningocele, 265
- N-acetylcysteine (NAC), 188
- nanotechnology, 340–1
- National Health and Social Life
Survey (NHSLs), 193
- neurohypophysitis, 1
- nifedipine, 120, 125, 132
- nitrofurantoin, 9
- nocturnal emissions, 112–13
- nursing considerations, 324
cancer patients, 326–7
erectile and ejaculatory
dysfunction, 326
in vitro fertilization patients,
325–6
semen analysis testing, 324
varicocele patients, 324–5
- obesity, 190, 196
- oligospermia, 13, 19
genetic testing, 20
findings, 21–2
- oocyte activation, 238–9
- oocyte evaluation, 225
- oocyte insemination, 225–6,
See also intracytoplasmic
sperm injection (ICSI)
- oocyte retrieval 225
- operating microscope, 304
learning to use, 307
- orchitis, 8
- orgasm, 105
disorders, 116, 211
- outcome metrics, 328–9
analysis and evaluation
methods, 329
costs, 328
effectiveness, 328–9
- ovarian hyperstimulation
syndrome (OHSS), 224,
229
- ovarian reserve testing
anti-müllerian hormone
(AMH), 222
antral follicle count, 222
FSH, 222
- ovarian stimulation. *See* in
vitro fertilization
(IVF); intrauterine
insemination (IUI)
- ovulation induction, 224
- oxidative stress, 187,
See also antioxidant
therapy
- oxytocin (OT), 112
anejaculation treatment, 115
- partner issues, 209
erectile dysfunction, 210
premature ejaculation, 213
- retarded ejaculation, 212
sexual desire disorders, 209
- pediatric issues
bladder extrophy, 265
cancer, 264
fertility preservation,
271–2
practical and ethical issues,
272
cryptorchidism, 263–4
iatrogenic injury to the vas
deferens, 264
imperforate anus, 264
myelomeningocele, 265
posterior urethral valves, 265
prune belly syndrome, 265
retractile testis, 265
testicular torsion, 265
varicocele, 262–3
- penile vibratory stimulation
(PVS), 115, 119, 125–6,
132
autonomic dysreflexia (AD)
induction, 120–1
bladder preparation, 121
candidates for, 119–20
contraindications, 121
devices, 120
ejaculatory failure, 122–3
goals, 120
history of, 119
home insemination,
125–6
personnel requirements, 121
responses, 122
retrograde ejaculation, 123
semen quality, 124
situating the patient, 121
success rate, 123
technique, 121–2
vibrator hygiene, 121
- penis
arterial flow, 50
hemangioendothelioma, 51
urinoma, 51
- percutaneous epididymal sperm
aspiration (PESA), 101–
2, *See also* surgical sperm
retrieval (SSR)
- percutaneous testicular fine
needle aspiration, 64
- pesticide exposure, 254
- Peyronie's disease, 10, 50
imaging, 46–7
- phosphodiesterase 5 inhibitors
(PDE5i), 198–9, 206, 211
- phospholipase C- ζ 1 (PLC ζ 1),
238–9
- phthalates, 254, 257
- physical examination, 9–11
endocrine-related infertility
assessment, 170
genital examination, 10–11
rectal examination, 11
- pituitary, 1, 169
diseases, 171–2

- congenital adrenal hyperplasia, 172
 craniopharyngioma, 171
 critical and chronic diseases, 172
 drugs, 172
 infarction/apoplexy, 172
 invasive diseases, 172
 traumatic brain injury, 172
 tumors, 171–2
 pollutant exposure prevention, 189–90
 polychlorinated biphenyl (PCB) exposure, 253–4
 polyglandular failure syndromes, 173
 posterior urethral valves, 265
 posthumous sperm cryopreservation, 290–1
 pre-implantation genetic diagnosis (PGD), 226–7
 pre-implantation genetic screening (PGS), 227
 premature ejaculation, 105, 130, 194, 212–13
 etiology, 213
 infertility management, 132
 management, 213
 partner/relationship issues, 213
 prevalence, 212–13
 principle component analysis, 339
 processus vaginalis, 150
 closure abnormalities, 151
 prolactin, 169
 male sexual function and, 195–6
 measurement, 170
 prolactin-secreting tumors, 171–2
 SSRI effects, 200
 prolactinoma, 9
 prostate
 cysts, 57, 74, 114
 ejaculatory function and, 106
 imaging, 57
 spinal cord injury and, 124
 ureter ectopic insertion, 58
 prostatitis, 8, 57
 granulomatous, 58
 proteomics, 338
 prune belly syndrome, 265
 puberty, 180
 Klinefelter syndrome, 180–1
 pudendal nerve, 109
 pyocele, 45
 pyospermia, 8
 radiotherapy, 9, 197,
See also cancer
 effects on spermatogenesis, 286
 fertility treatment after, 272
 testicular sperm extraction, 166
 gonadal shielding, 271
 gonadotoxic effects, 269–70
 pediatric, 264
 risks to offspring conceived following therapy, 270–1
 safety to conceive after, 286, 294–5
 rat use in training and research, 318–21
 postoperative evaluation, 320–1
 vasal obstruction model, 318
 vasoepididymostomy, 318–20
 vasovasostomy, 318
 reactive oxygen species (ROS).
See also antioxidant therapy 15, 187
 recombinant FSH, 174
 rectal examination, 11
 Reifenstein's syndrome, 173
 relationship issues, 209
 premature ejaculation, 213
 sexual desire disorders, 209
 reproductive history, 8
 respiratory tract infections, 9
 retarded ejaculation, 105, 211–12
 etiology, 211–12
 management, 212
 partner issues, 212
 rete testis dilation, 44
 retractile testis, 157, 265
 infertility and, 157–8
 scrotal orchiopexy, 158–9
 retrograde ejaculation, 131
 following penile vibratory stimulation, 123
 management, 132
 retroperitoneal lymph node dissection (RPLND), 9, 131
 obstructive effects, 269
 Robertsonian translocations, 21
 round cells, 14
 scrotal orchiopexy, 157–9
 scrotal pearls/macroliths, 45–6, 150
 scrotum
 imaging, 38
 surgery, 9
 selective androgen receptor modulators (SARMs), 341
 selective serotonin reuptake inhibitors (SSRIs), 199–200
 premature ejaculation management, 213
 selenium, 189
 semen analysis, 13–14
 ejaculatory duct obstruction evaluation, 73–4
 future advances, 341
 nursing considerations, 324
 reference ranges, 13
 varicocele and, 263
 viscosity, 13
 semen quality
 environmental impacts, 253, 257–9
 pitfalls with
 epidemiological studies, 253–4
 spinal cord injury and, 123–4
 seminal vesicles, 48–50
 agenesis, 48–50
 aspiration, 75
 calcifications, 48
 congenital absence, 52
 cysts, 50, 74
 imaging, 48–50
 spinal cord injury and, 124
 seminal vesiculography, 75
 seminiferous tubules, 2–3
 seminoma, 41
 serotonin, 112
 Sertoli cells, 3, 169
 functions, 3, 5
 sex hormone-binding globulin (SHBG), 170
 sex status examination, 208
 sex therapy, 204–5
 partner/relationship issues, 209
 referral, 206
 sex-determining region on the Y chromosome (SRY) gene, 2
 sexual arousal, 105
 male arousal disorder, 210–11, *See also* erectile dysfunction (ED)
 sexual aversion disorder (SAD), 210
 sexual desire, 105
 disorders, 209–10
 infertility and, 209
 management, 209–10
 partner/relationship issues, 209
 infertility impact, 193
 sexual dysfunction, 105–6, 193, *See also* combined male sexual dysfunction and infertility; *specific conditions*
 delayed/retarded ejaculation, 211–12
 desire disorders, 209–10
 disorders leading to infertility, 205
 ethical issues, 214
 etiology, 206
 evaluation, 205
 follow-up, 209
 male arousal disorder, 210–11, *See also* erectile dysfunction (ED)
 male orgasmic disorder, 211
 management guidelines, 206
 partner/relationship issues, 209
 premature ejaculation, 212–13
 prevention in infertile couples, 214
 psychogenic, 194
 sex status examination, 208
 sexual aversion disorder (SAD), 210
 sexual pain disorders, 213–14
 Sexual Tipping Point® (STP) model, 206–8
 systemic diseases associated with, 196–8
 sexual history, 8
 sexual pain disorders, 213–14
 sexual response, 106,
See also ejaculation
 anatomy and physiology of, 106–12
 neurochemical regulation of CNS, 111–12
 spinal ejaculatory center, 109–11
 supraspinal center and modulation, 111
 phases of, 105, 107
 testosterone role, 195
 Sexual Tipping Point® (STP) model, 206–8
 sildenafil, 198–9, 206
 silicone tubing use in training, 312–15
 smoking, 9, 189, 222
 sonography, 58, 340
 ejaculatory ducts, 55–7
 penis, 46–8
 prostate, 57
 scrotum, 38
 testis, 38–42
 varicocele, 140
 vas deferens, 50–5
 sperm, 4
 agglutination, 14
 cervical mucus penetration, 29
 antisperm antibody effects, 28
 chromatin structure, 242–3
 chromosome content, 240, 243
 DNA integrity, 15–16, 239–42
 FISH analysis, 15–16
 genomic competence, 237
 maturation, 5
 morphology, 14
 motility, 13–14
 antisperm antibody effects, 29
 spinal cord injury and, 123–4
 storage, 5
 viability, 14
 spinal cord injury and, 123–4
 zona pellucida binding assays, 15

Index

- sperm “swim-up” technique, 235
sperm aspiration. *See* epididymal sperm aspiration
sperm banking, 271,
See also sperm cryopreservation
Sperm Chromatin Dispersion (SCD), 15, 240–1
Sperm Chromatin Structure Assay (SCSA), 15, 240–1
sperm count, 13
sperm cryopreservation, 280
before cancer treatment, 197, 264, 271, 281–4
effects of, 294
following vasovasostomy, 82
for assisted reproduction procedures, 290
historical perspective, 280–1
indications, 281
malignant disease, 281–4
non-malignant disease, 286
length of storage time, 295–6
methodology, 292–4
freeze-drying, 293–4
media, 292
protocols, 292–3
vitrification, 293
posthumous, 290–1
quality of thawed sperm, 296
source of male gametes, 291–2
electroejaculation, 292
intra-operative cryopreservation, 292
MESA, 291
TESE, 291–2
tracking of specimens, 294
usage of cryopreserved sperm, 296–7
sperm function testing, 14–15
sperm penetration assay, 15
sperm retrieval.
See electroejaculation; microsurgical epididymal sperm aspiration (MESA); percutaneous epididymal sperm aspiration (PESA); surgical sperm retrieval (SSR); testicular sperm extraction (TESE)
sperm washing, 234–5
spermatic cord
block, 62
counter current heat exchange, 2
examination, 11
hematoma, 48
liposarcoma, 48
masses, 46
spermatocele, 11, 45
imaging, 45
spermatocytes, 4
spermatogenesis, 4–5
chemotherapy effects on, 284–6
genetic factors, 5
hormonal regulation, 5
medication effects on, 286–90
radiotherapy effects on, 286
stimulation of, 1
temperature and, 157
spermatogonia, 4
spermatogonial stem cells (SSCs), 338
cryopreservation, 272, 338
spinal cord injury (SCI), 119, 131
decision-making, 134
electroejaculation and, 115, 125
home insemination, 125–6
penile vibratory stimulation (PVS) and, 119, 125–6
autonomic dysreflexia (AD) induction, 120–1
candidates for, 119–20
success rate, 123
semen quality, 123–4
treating the couple, 124–6
spinal ejaculatory center, 109–11
steroid feedback loop, 1
stimulated acrosome reaction (SAR) score, 14–15
stress, sexual dysfunction and, 194
sulfasalazine, 9, 289
surgical history, 9
surgical sperm retrieval
comparative cost-effectiveness, 254
surgical sperm retrieval (SSR), 124, 134,
See also microsurgical epididymal sperm aspiration (MESA); percutaneous epididymal sperm aspiration (PESA); testicular sperm extraction (TESE)
comparative cost-effectiveness, 333–4
suturing technique, 309–12
teratocarcinoma, 41
teratoma, 41
terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL), 15, 239
testicular arteries, 2
testicular biopsy, 61–4
complications, 65
indications, 61
nonobstructive azoospermia, 62, 161–2
nursing considerations, 325–6
obstructive azoospermia, 61–2
open, 62–4
surgical technique, 62–4
percutaneous, 64
surgical technique, 64
results, 65
testicular cancer, 9, 42, 276
chemotherapy, 286
evaluation, 276
nonpalpable masses, 276–7
pathologic diagnosis, 278
testis-preserving surgical approach, 276–8
testis-sparing surgical approach, 277
indications, 277
testicular cysts, 41
testicular dysgenesis syndrome (TDS), 254–6, 258–9
testicular failure, 172
primary germ cell failure, 173
primary testicular failure, 172–3
treatment, 174–5
testicular germ cell tumors, 173
testicular hematoma, 40
following biopsy, 65
testicular hypovascularity, 38
testicular microlithiasis, 38–41
testicular sperm aspiration, 64–5
testicular sperm extraction (TESE), 19,
See also surgical sperm retrieval (SSR)
azoospermia after chemotherapy/radiotherapy, 166
effectiveness, 331–3
Klinefelter syndrome, 181, 183
microdissection TESE (microTESE), 161, 164–5
after failed TESE, 165
Klinefelter syndrome, 166
predictors of success, 165–6
results, 165
sperm processing, 165
nursing considerations, 326
preoperative preparation, 162–3
sperm cryopreservation, 291–2
surgical approaches, 163–4
treatment considerations, 163
testicular torsion, 173, 265
testis, 2, 38, 169
anatomy, 2
blood–testis barrier, 4
examination, 10–11
functional development in Klinefelter syndrome, 180–1
imaging, 38–42
intratesticular arterial flow, 38
measurement, 10–11
retractile. *See* retractile testis
tissue cryopreservation, 272
undescended (UDT), 157, 263–4
varicocele effects, 138, 140, 262
testosterone, 169
aging effects, 2
androgen resistance, 173
assay, 170
cognitive impairment and, 182
ejaculatory function and, 112, 195
Klinefelter syndrome, 180
production of, 1
regulatory function, 1
sexual dysfunction and, 194–5
treatment for low levels, 162–3. *See also* testosterone replacement therapy
empiric therapy, 189
varicocele relationships, 200
testosterone replacement therapy, 174–5
effects on fertility, 200
Klinefelter syndrome, 182–3
tetracycline, 289
total sperm count, 13
toxicological studies
abnormal fetal development, 257
laboratory animals, 256–7
training. *See* microsurgical training
translocations, 21–2
transrectal ultrasonography (TRUS), 58, 71
ejaculatory ducts, 57, 74–5,
See also sonography
transurethral endoscopy, 71
transurethral resection of the ejaculatory duct (TURED), 57, 95–6, 98
complications, 97–8
outcomes, 97
traumatic brain injury, 172
Trypan blue stain, 14
tubal factor infertility, 219–20
distal tubal disease, 220
proximal tubal disease, 220
ultrasound. *See* sonography
undescended testis (UDT), 157, 263–4
management, 264
unexplained infertility, 221
ureter, ectopic insertion, 58
urinary tract infections, 222
urinoma, 51
uterus evaluation, 222
vanishing testes syndrome, 173
varicocele, xi, 11, 47, 137
diagnosis, 139–40

- etiology, 137–8
examination, 11
fertility relationships, 138–9
grading, 11, 140
imaging, 45–6, 140
intratesticular, 46
nonobstructive azoospermia
and, 162
nursing considerations, 324–5
pathophysiology, 138
pediatric aspects, 262–3
prevalence, 137
testicular growth retardation,
262
testosterone relationships,
200
treatment, 140–1, 145
 alternative approaches,
 143–4
 comparative cost-
 effectiveness, 333–4
 complications, 145–6
 considerations, 140
 effectiveness, 331–2
- microsurgical sub-inguinal
 varicocelectomy, 141–2
 outcomes, 144–5
 pediatric varicocele, 262–3
vas deferens, 5, 68
 congenital absence, 52,
 See also congenital
 bilateral absence of the
 vas deferens (CBAVD)
 ectopic insertion, 55
 examination, 11
 iatrogenic injuries, 264
 imaging, 45, 50–5
 mobilization and fixation, 88
 obstruction, vasography,
 68–70
vasectomy reversal, 62, 68,
 See also vasovasostomy
 (VV)
 comparative cost-
 effectiveness, 333
 effectiveness, 330–1
vasectomy segment use in
 training, 316–17
- vasoepididymostomy (VE),
 79–80, 85
 complications, 89–90
 cost-effectiveness, 333
 history of, 85
 outcomes, 89
 surgical techniques, 87–9
 end-to-end anastomosis,
 87–8
 end-to-side techniques,
 84–91
vasography, 68, 71
 alternatives, 71
 anatomy, 68
 complications, 71
 indications, 68
 ejaculatory duct
 obstruction, 74
 technique, 68–9
vasovasostomy (VV), 79
 inguinal hernia repair and,
 82
 new technical modifications,
 82
 patient selection, 79
- results, 80–2
 technique, 79–80
Viagra™, 198–9
vibrators. *See* penile vibratory
 stimulation (PVS)
vitamin C, 187–8
vitamin E, 188
vitrification, 293
- X-chromosome inactivation,
 180
- Y chromosome, 20
 microdeletions (YCMD),
 22
 assay, 20, 22
 testicular sperm extraction
 and, 166
yolk sac tumors, 41
Young's syndrome, 9
- zona pellucida induced
 acrosome reaction
 (ZPIAR), 15